Ajinomoto
APAC
Tokyo
,
Japan
Multinational
FOUNDED
1909
HEADCOUNT
10000+
FUNDING
Public
Keywords:
fermentation, precision_fermentation, amino_acids, metabolic_engineering, bacteria, CDMO, therapeutics, vaccines, gene_editing, mammalian_cells, specialty_chemicals, nutrition, cell_free, biocatalysis, animal_nutrition
BUSINESS
Ajinomoto Co., Inc. (TSE: 2802), founded in 1909 and headquartered in Tokyo, Japan, is a publicly traded global food and biotechnology company. FY2024 sales were approximately ¥1.53 trillion (~$10.6B) with around 35,000 employees across 31 countries. The company operates Bio-Pharma Services (CDMO across small molecules, large molecules, ADCs, oligonucleotides, and gene therapy), pharmaceutical and specialty amino acids, electronic materials, and specialty fermentation ingredients. The November 2023 acquisition of Forge Biologics for $620M added a 200,000 sq ft AAV gene therapy and plasmid CDMO facility in Columbus, Ohio; Ajinomoto sold Ajinomoto Althea to Packaging Coordinators Inc. in May 2025 and has progressively divested commodity feed-grade amino acid operations, including the 2021 sale of its European feed amino acid plant to Métabolic Explorer.
BIOTECH INVOLVEMENT
Operates one of the world's largest pharmaceutical-grade and specialty amino acid fermentation businesses, with proprietary strain engineering and decades of fermentation know-how dating to the 1956 commercial launch of amino acid infusions. Has progressively divested commodity feed-grade amino acid operations while reinvesting in specialty applications including AjiPro-L rumen-protected lysine, sports nutrition, and pharmaceutical amino acids. The Bio-Pharma Services CDMO platform spans Belgium, US, Japan, and India, with capabilities in microbial and mammalian cell culture, ADCs, oligonucleotides, and AAV viral vector and plasmid DNA manufacturing for gene therapy customers.
TECHNOLOGY PLATFORM
AminoScience
PRIMARY PRODUCTS
AJI-NO-MOTO umami seasoning; amino acids; pharmaceuticals